OverviewChartNewsTraderScreen

ALMIRALL S.A. EO -,12/  ES0157097017  /

Frankfurt
2024-04-26  8:08:11 AM Chg. +0.1500 Volume Bid9:38:59 PM Ask9:38:59 PM High Low
8.4000EUR +1.82% 0
Turnover: 0.0000		 -Bid Size: - -Ask Size: - 8.4000 8.4000
GlobeNewswire 04-16 Eloxx Pharmaceuticals Provides ELX-02 and ZKN-013 Program Updates
GlobeNewswire 03-13 Almirall and Eloxx Pharmaceuticals Enter into Exclusive Agreement to license ZKN-013 for rare dermat...
GlobeNewswire 03-05 Paratek Pharmaceuticals Announces Positive Efficacy Data for NUZYRA® as Post-Exposure Prophylaxis of...
GlobeNewswire 01-10 Absci Appoints Professor Sir Mene Pangalos to its Board of Directors
GlobeNewswire 2023-11-14 Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
GlobeNewswire 2023-11-14 Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for de...
GlobeNewswire 2023-10-05 Paratek Pharmaceuticals to Present NUZYRA Data at IDWeek 2023
GlobeNewswire 2023-09-21 Gurnet Point Capital and Novo Holdings A/S Complete Acquisition of Paratek Pharmaceuticals, Inc.
GlobeNewswire 2023-09-18 Paratek Pharmaceuticals Announces Stockholder Approval of Acquisition by Gurnet Point Capital and No...
GlobeNewswire 2023-09-12 Second Leading Independent Proxy Advisory Firm Glass Lewis Recommends Paratek Pharmaceuticals Stockh...
GlobeNewswire 2023-09-07 Leading Independent Proxy Advisory Firm ISS Recommends Paratek Pharmaceuticals Stockholders Vote FOR...
GlobeNewswire 2022-03-25 ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corpo...
GlobeNewswire 2022-03-16 Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
GlobeNewswire 2022-03-15 ASLAN Pharmaceuticals Appoints Dermatology Veteran Dr Alex Kaoukhov as Chief Medical Officer
GlobeNewswire 2022-03-14 Paratek Pharmaceuticals Announces Full-Year 2021 Revenue of $130.2 Million
GlobeNewswire 2022-03-08 Paratek Pharmaceuticals Announces the Publication of Data from an Investigator-Initiated Study of NU...
GlobeNewswire 2022-03-02 Paratek Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 14, ...
GlobeNewswire 2022-03-01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2022-02-01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2022-01-03 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2021-12-16 China's National Medical Products Administration Approves NUZYRA® (omadacycline) for the Treatment o...
GlobeNewswire 2021-12-01 Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire 2021-11-10 Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
GlobeNewswire 2021-11-08 Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
GlobeNewswire 2021-11-04 Athenex Provides Third Quarter 2021 Corporate and Financial Update